Xlear

❗Article Status Notice: This Article is a stub

---

This article is underdeveloped, and needs additional work to meet the wiki's Content Guidelines and be in line with our Mission Statement for comprehensive coverage of consumer protection issues. Learn more ▼

Issues may include:

• This article needs to be expanded to provide meaningful information
• This article requires additional verifiable evidence to demonstrate systemic impact
• More documentation is needed to establish how this reflects broader consumer protection concerns
• The connection between individual incidents and company-wide practices needs to be better established
• The article is simply too short, and lacks sufficient content

How you can help:

• Add documented examples with verifiable sources
• Provide evidence of similar incidents affecting other consumers
• Include relevant company policies or communications that demonstrate systemic practices
• Link to credible reporting that covers these issues
• Flesh out the article with relevant information

This notice will be removed once the article is sufficiently developed. Once you believe the article is ready to have its notice removed, visit the Discord (join here) and post to the #appeals channel, or mention its status on the article's talk page.

Xlear

Basic information
Founded	2000
Legal Structure	Private
Industry	Nasal sprays
Official website	https://xlear.com

Xlear is a Utah-based nasal spray company which falsely advertised its nasal spray as a COVID-19 preventative and treatment. In 2021, the FTC sued Xlear for this false claim.

Background

Xlear was founded in 2000, and creates xylitol-based sinus and oral care products.

Consumer Impact Summary

In 2021, Xlear was sued by the FTC for false advertising. In 2025, Xlear filed a lawsuit against the FTC which would make it harder for the FTC to punish unsubstantiated health claims, thereby harming consumers of medical products.

Incidents

False COVID-19 medical claims (October 28, 2021)

On the 28^th of October, 2021, the US Department of Justice filed a complaint against Xlear, Inc. on the behalf of the FTC for falsely marketing its nasal spray as an effective COVID-19 preventative, seeking to impose financial penalties on the company and to bar them from continuing to make unsubstantiated medical claims about their products.

According to the complaint, since at least March 2020, Xlear marketed their nasal sprays as an effective preventative and treatment against COVID-19, claiming that their nasal sprays provide up to 4 hours of protection against COVID-19. The FTC alleged that Xlear lacked a factual or scientific base to support their claims.

The Trump Justice Department, on the behalf of the FTC, asked for the case to be dismissed with prejudice on the 10^th of March, 2025, but did not explain its reasoning for the dismissal.

On the 18^th of June, 2025, Xlear filed a lawsuit against the FTC in an attempt to make it harder for the FTC to go after health claims. The company's central argument is that the FTC Act prohibits only false or deceptive statements – not unsubstantiated ones.